Syros Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Syros Pharmaceuticals

09/08/2022 14:32

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of 54 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 41 cents per share.
    * Revenue rose 21.6% to $6.28 million from a year ago;
analysts
expected $4.57 million. 
    * Syros Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 54 cents​.
    * The mean earnings estimate of analysts had risen by
about 14.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Syros Pharmaceuticals Inc shares had risen by 1.3% this
quarter and lost 70.1% so far this year.
    * The company reported a quarterly loss of $34.48 million.
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $9.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.41          -0.54          Missed
 Mar. 31 2022      -0.47          -0.40          Beat
 Dec. 31 2021      -0.47          -0.38          Beat
 Sep. 30 2021      -0.44          -0.41          Beat